Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets

PALATIN TECHNOLOGIES INC

2026-Q1 EPS reported -$19.71 vs consensus -$1.26 ▼ miss (-1469.5%)

Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.
Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.
Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.
Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.
DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.